{"id":8930,"date":"2024-06-20T15:15:11","date_gmt":"2024-06-20T13:15:11","guid":{"rendered":"https:\/\/www.seventure.fr\/?p=8930"},"modified":"2024-07-31T14:12:02","modified_gmt":"2024-07-31T12:12:02","slug":"tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/","title":{"rendered":"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma."},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,106],"tags":[],"class_list":["post-8930","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-biotech-pharmaceuticals"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma. | Seventure<\/title>\n<meta name=\"description\" content=\"Tubulis announced today that the first patient has been treated in its first Phase I\/IIa trial. The study is evaluating Tubulis\u2019 next-generation antibody-drug conjugate (ADC) TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Romane Brunet\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/\",\"name\":\"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma. | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2024-06-20T13:15:11+00:00\",\"dateModified\":\"2024-07-31T12:12:02+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\"},\"description\":\"Tubulis announced today that the first patient has been treated in its first Phase I\/IIa trial. The study is evaluating Tubulis\u2019 next-generation antibody-drug conjugate (ADC) TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\",\"name\":\"Romane Brunet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"caption\":\"Romane Brunet\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma. | Seventure","description":"Tubulis announced today that the first patient has been treated in its first Phase I\/IIa trial. The study is evaluating Tubulis\u2019 next-generation antibody-drug conjugate (ADC) TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/","twitter_misc":{"Written by":"Romane Brunet"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/","url":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/","name":"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma. | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2024-06-20T13:15:11+00:00","dateModified":"2024-07-31T12:12:02+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"description":"Tubulis announced today that the first patient has been treated in its first Phase I\/IIa trial. The study is evaluating Tubulis\u2019 next-generation antibody-drug conjugate (ADC) TUB-040 in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options.","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/tubulis-doses-first-patient-in-phase-i-iia-trial-investigating-adc-candidate-tub-040-in-ovarian-cancer-and-lung-adenocarcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Tubulis Doses First Patient in Phase I\/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma."}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5","name":"Romane Brunet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","caption":"Romane Brunet"},"url":"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=8930"}],"version-history":[{"count":5,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8930\/revisions"}],"predecessor-version":[{"id":9063,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/8930\/revisions\/9063"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=8930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=8930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=8930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}